Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.40 USD
Change Today +0.05 / 14.29%
Volume 14.2K
As of 8:10 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

champions oncology inc (CSBR) Snapshot

Open
$0.41
Previous Close
$0.35
Day High
$0.41
Day Low
$0.40
52 Week High
03/10/14 - $1.15
52 Week Low
03/2/15 - $0.20
Market Cap
26.8M
Average Volume 10 Days
25.1K
EPS TTM
$-0.15
Shares Outstanding
66.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHAMPIONS ONCOLOGY INC (CSBR)

champions oncology inc (CSBR) Related Bloomberg News

View More Bloomberg News

champions oncology inc (CSBR) Related Businessweek News

No Related Businessweek News Found

champions oncology inc (CSBR) Details

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers POS products, including non-core related POS products that provide access to oncologists in tumor types and patient’s history of treatment; and gene sequencing that analyzes the genetic makeup of patient’s tumor for the purpose of identifying useful drugs. In addition, the company offers Translational Oncology Solutions (TOS), including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies, which uses vivo studies and bioinformatics analysis to predict the efficacy of experimental oncology drugs or approved drugs as stand-alone therapies or in combination with other drugs. Further, it provides a bank of tumors that are acquired, collected, processed, validated, and stored for the use in TOS. The company markets its products through Internet, word of mouth, and a network of sales force. It serves patients, physicians, and drug development companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. is headquartered in Hackensack, New Jersey.

60 Employees
Last Reported Date: 07/28/14

champions oncology inc (CSBR) Top Compensated Officers

Chief Executive Officer, Secretary and Direct...
Total Annual Compensation: $53.2K
President and Director
Total Annual Compensation: $43.5K
Executive Vice President and General Manager ...
Total Annual Compensation: $181.3K
Compensation as of Fiscal Year 2014.

champions oncology inc (CSBR) Key Developments

Champions Oncology, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended October 31, 2014

Champions Oncology, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended October 31, 2014. For the quarter, the company reported total operating revenue of $1,882,000 against $2,383,000 a year ago. Loss from operations was $3,666,000 against $1,701,000 a year ago. Net Loss before income tax expense was $3,068,000 against $2,315,000 a year ago. Net loss was $3,078,000 or $0.05 basic EPS against $2,318,000 or $0.03 basic EPS a year ago. Non-GAAP net loss was $2,258,000 or $0.04 basic EPS against $1,842,000 or $0.02 basic EPS a year ago. For the six months, the company reported total operating revenue of $3,793,000 against $5,403,000 a year ago. Loss from operations was $7,387,000 against $2,472,000 a year ago. Net Loss before income tax expense was $6,669,000 against $4,550,000 a year ago. Net loss was $6,684,000 or $0.04 basic EPS against $4,556,000 or $0.02 basic EPS a year ago. Net cash used in operating activities was $5,247,000 against $1,902,000 a year ago. Purchases of property and equipment were $71,000 against $76,000 a year ago. Non-GAAP net loss was $5,057,000 or $0.08 basic EPS against $3,528,000 or $0.05 basic EPS a year ago.

Champions Oncology, Inc. to Report Q2, 2015 Results on Dec 12, 2014

Champions Oncology, Inc. announced that they will report Q2, 2015 results Pre-Market on Dec 12, 2014

Champions Oncology, Inc., Q2 2014 Earnings Call, Dec 12, 2014

Champions Oncology, Inc., Q2 2014 Earnings Call, Dec 12, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CSBR:US $0.40 USD +0.05

CSBR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CSBR.
View Industry Companies
 

Industry Analysis

CSBR

Industry Average

Valuation CSBR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHAMPIONS ONCOLOGY INC, please visit www.championsoncology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.